Neurotrophic tyrosine receptor kinase fusion, or NTRK, has emerged in the last six years as a rare, but targetable alteration in several cancers. Dr. Herbert Loong, clinical assistant professor in the department of clinical oncology and deputy medical director of the Phase 1 Clinical Trials Center of The Chinese University of Hong Kong, joins Lung Cancer Considered host Dr. Stephen Liu to discuss NTRK and what impact it may have on lung cancer research and treatment.

Dr. Herbert Loong
Dr. Stephen Liu